Gene-editing drugs are opening a new frontier in medicine

A groundbreaking study in the *New England Journal of Medicine* introduces VERVE-102, a gene-editing drug designed to modify the PCSK9 gene in liver cells using CRISPR technology. The drug aims to replicate the cardiovascular benefits observed in individuals born with naturally protective versions of PCSK9, which can reduce coronary heart disease risk by up to 50% or eliminate it entirely. Currently, treatments like statins and inclisiran lower LDL cholesterol but require long-term use—daily pills or twice-yearly injections. VERVE-102, however, could offer a one-time intervention to achieve similar genetic advantages. Early trial data from high-risk patients suggest this approach may be viable, though larger studies are needed to confirm its safety and efficacy. Eli Lilly acquired the drug’s developer last year, positioning itself to capitalize on a potential medical breakthrough. Unlike existing cholesterol medications, which provide modest risk reductions (e.g., ezetimibe’s 6% relative risk cut), VERVE-102 could offer transformative, lifelong protection if administered early in life. The shift toward preventive, gene-targeted therapies raises ethical debates about medicalizing normal aging. While some criticize overmedicalization, others embrace interventions that extend healthy lifespans. A single dose of VERVE-102 could bridge this gap by permanently altering disease risk without daily adherence. The phase 1 trial results, though preliminary, highlight medicine’s evolving focus—from treating diseases to preventing biological decay. If successful, VERVE-102 could redefine cardiovascular care, offering a permanent solution where pills and lifestyle changes fall short.